AbbVie and Pfizer diverge on revenue and leverage as patents expire
AbbVie grew revenue 9 percent to $61.2 billion in fiscal 2025 while Pfizer’s slipped 1.6 percent to $62.6 billion, a split that frames the choice for
McKesson
Every Fin-node story mentioning McKesson — 1 story, newest first.
McKesson · 1 story